|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
LINC00909 promotes tumor progression in human glioma through regulation of miR-194/MUC1-C axis.
|
31132669 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In PDA, MUC1 promotes tumor progression and metastasis via signaling through its cytoplasmic tail (MUC1-CT) and interacting with other oncogenic signaling molecules.
|
29467938 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
|
29204701 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MUC1 is a transmembrane mucin that can promote cancer progression, and its upregulation correlates with a worse prognosis in colon cancer.
|
28717171 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
As MUC1 and galectin-3 are both commonly overexpressed in most types of epithelial cancers, their interaction and impact on EGFR activation likely makes important contribution to EGFR-associated tumorigenesis and cancer progression and may also influence the effectiveness of EGFR-targeted cancer therapy.
|
28731466 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This mini-review focuses on the potential importance of this MUC1-C program in cancer progression.
|
28302417 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mucin-1 (MUC1) affects cancer progression in lung adenocarcinoma, and its aberrant expression pattern has been correlated with poor tumor differentiation and impaired prognosis.
|
27481516 |
2016 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, these findings suggest MUC1 regulates the expression of MRP1 and provides a direct link between cancer progression and chemoresistance in mammary carcinoma cells.
|
27221150 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The cytoplasmic tail of MUC1 (MUC1-CT) partakes in oncogenic signaling, resulting in accelerated cancer progression.
|
26035123 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Inhibiting MUC1 using miRNAs appears thus as an attractive strategy to reduce cancer progression.
|
26036346 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MUC1 is a membrane-anchored mucin and its cytoplasmic tail (CT) can interact with many signaling pathways and act as a co-transcription factor to activate genes involved in tumor progression and metastasis.
|
24504508 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mucin 1 (Muc1) is a tumor-associated glycoprotein and has an important role in cancer progression and metastasis.
|
24410135 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, an immunohistochemical analysis for abnormalities in the expression of five molecular parameters: MUC1, p16, p53, Smad4 and sonic hedgehog, which are associated with tumor progression, was performed.
|
24297432 |
2014 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Specific MUC1 splice variants (i.e., MUC1/C, D, and Z) are correlated with tumor progression in ESCC, whereas MUC1/B-previously suggested as a "normal" variant in some other cancers-has protective effects and is associated with more favorable tumor behavior and better prognosis.
|
24718884 |
2014 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Even though immune cells express low MUC1 levels, their modulations of MUC1 are important in tumor progression.
|
23873692 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that signaling through MUC1 influences cancer progression by regulating transcription of microRNAs that are associated with the process of metastasis.
|
24143167 |
2013 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with β-catenin in tumor progression.
|
21466814 |
2011 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
On a global scale, MUC1.CT preferentially targets genes related to invasion, angiogenesis and metastasis, suggesting that MUC1.CT signaling contributes to establishing a reactive tumor microenvironment during tumor progression to metastatic disease.
|
20697347 |
2010 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of MUC1 is closely associated with cancer progression and metastasis, leading to poor prognosis.
|
19141292 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.
|
19549898 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The aberrant expression of membrane mucins such as Muc1 and Muc4 by tumor cells has been shown to engage signaling pathways that promote cellular properties associated with tumor progression.
|
19293191 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
|
18713982 |
2008 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Loss of MUC2 is an adverse prognostic factor in MMR-proficient and MLH1-negative CRC, whereas MUC1 expression is associated with tumour progression in MMR-proficient CRC only.
|
16816167 |
2007 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MUC1 is a transmembrane mucin that plays an important role in tumor progression.
|
17409826 |
2006 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
High MUC1 immunoreactivity displayed a significant correlation with tumor progression as reflected by vascular invasion (P<0.001), whereas high expression of MUC5AC significantly correlated with neural invasion (P = 0.022) and advanced ICC stage (P = 0.008).
|
16124042 |
2005 |